Caladrius biosciences, inc. (CLBS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Operating Expenses:
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,489

7,559

5,888

5,866

3,172

5,276

4,117

4,488

4,055

4,078

3,706

4,359

2,523

2,751

4,433

3,372

3,772

-13,928

2,177

2,210

19,590

16,475

19,407

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,228

6,182

4,808

5,798

3,368

4,163

4,012

3,677

3,825

3,344

2,975

4,235

2,392

2,509

3,747

2,735

2,955

-9,311

1,891

1,790

14,276

11,232

12,911

Gross profit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

686

636

817

-4,616

285

420

5,314

5,242

6,495

Research and development

1,499

2,767

3,004

2,988

2,038

1,508

1,701

2,123

2,262

4,652

3,187

4,277

3,726

3,375

2,958

4,488

5,876

3,179

6,315

7,600

6,803

10,169

8,469

5,796

4,759

5,297

4,486

3,972

3,161

2,961

2,828

2,714

1,947

1,833

1,540

1,591

2,755

1,679

2,133

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

9,400

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

2,558

2,315

2,068

2,358

2,554

2,288

2,062

2,146

2,897

2,668

2,942

3,432

2,706

658

2,768

2,917

6,458

5,034

5,147

8,736

11,087

6,496

7,894

7,446

8,970

5,931

5,557

4,322

5,801

5,222

5,947

4,732

6,412

3,207

5,975

8,868

9,634

9,306

7,865

Total operating expenses

4,057

5,082

5,072

5,346

4,592

3,796

3,763

4,269

5,159

7,320

6,129

7,710

6,432

-2,194

5,727

7,405

18,562

67,269

16,271

31,535

21,260

20,829

20,376

16,919

17,554

14,572

13,019

12,529

11,355

20,133

8,775

7,447

8,359

5,041

7,516

10,459

12,390

10,986

-

Operating loss

-4,057

-5,082

-5,072

-5,346

-4,592

-3,796

-3,763

-4,269

-5,159

-7,320

-6,129

-7,710

-6,432

-5,295

-5,727

-7,405

-11,073

-59,709

-10,383

-25,668

-18,087

-15,552

-16,258

-12,430

-13,498

-10,494

-9,312

-8,170

-8,831

-7,942

-8,089

-6,811

-7,542

-9,658

-7,230

-10,039

-7,075

-5,743

-3,502

Other income:
Investment income, net

71

129

175

209

227

238

214

194

178

135

176

4

-44

4

5

8

5

13,324

-410

5,354

-546

3,988

-687

-185

-189

-1,863

179

57

10

-4,351

-74

24

87

487

1,292

555

-250

45

149

Interest expense

-

-

0

0

-

0

0

2

3

5

8

204

158

148

368

335

926

477

552

547

550

372

183

105

94

73

98

65

43

217

384

450

524

456

632

705

852

10

6

Total other income

71

129

175

209

227

238

214

192

175

129

168

-199

-203

-144

-363

-327

-921

12,847

-963

4,807

-1,096

3,616

-870

-291

-283

-1,936

80

-7

-32

-4,568

-459

-426

-436

31

660

-150

-1,102

35

143

Loss before benefit from income taxes and noncontrolling interests

-

-

-

-

-

-

-

-

-

-7,190

-5,961

-7,909

-6,635

-5,439

-6,090

-7,732

-11,994

-46,861

-11,346

-20,861

-19,184

-11,936

-17,129

-12,722

-13,782

-12,430

-9,231

-8,178

-8,864

-12,511

-8,548

-7,237

-7,979

-

-

-

-

-

-

Loss from continuing operations before provision for income taxes and noncontrolling interests

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,190

-8,178

-5,708

-3,359

Income Tax Expense (Benefit)

-

-

-

-

-

-

-

-

-

-3,225

-2,413

-5,887

0

-53

0

0

53

-13,633

46

-3,703

46

-246

47

47

47

287

44

447

0

-175

0

0

0

-

-

-103

592

285

402

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-3,964

-3,547

-2,022

-6,635

-

-6,090

-7,732

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,336

-8,548

-7,237

-7,979

-

-6,570

-10,086

-

-

-

Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

-

-

-

-

-

-

-

-

-

1,069

0

40,487

-3,157

-

-1,196

-151

-

-

-

-

-

-

-

-

-

-

-

-

-

-

152

-26,184

-1,227

-19,878

-758

-451

-928

-

-

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-3,986

-4,953

-4,897

-5,137

-4,365

-3,558

-3,549

-4,077

-4,984

-2,895

-3,547

38,465

-9,793

-6,089

-7,287

-7,884

-12,047

-33,228

-11,392

-17,158

-19,231

-11,690

-17,176

-12,769

-13,830

-12,718

-9,276

-8,625

-8,864

-15,343

-8,395

-33,422

-9,206

-29,016

-7,328

-10,537

-9,699

-5,994

-3,761

Less - net income attributable to noncontrolling interests

4

3

1

3

2

1

1

-1

-2

56

-119

-54

-64

-51

-59

-63

-66

-31

-16

-31

-44

-78

-202

-164

-148

-184

-205

-50

-63

-38

-59

-86

-101

-

-35

-14

-

-

-

Less - net income attributable to noncontrolling interests

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

473

1,145

1,611

Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders

-3,990

-

-

-

-4,367

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,505

-8,410

-20,505

-9,348

-19,009

-7,346

-10,605

-10,172

-7,140

-5,373

Less - net loss from discontinued operations attributable to noncontrolling interests

-

-

-

-

-

-

-

-

-

-0

0

-199

-368

-

-345

13

-

-

-

-

-

-

-

-

-

-

-

-

-

200

74

-12,830

243

-

53

82

-

-

-

Warrant inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,012

-

-

-

0

-

-

-

-

Warrant inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,012

-

-

-

0

-

-

-

-

Payment for warrant inducement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,012

-

-

-

-

-

-

-

-

Preferred dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

67

88

107

-

150

170

-

-

-

Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders

-

-

-4,898

-5,140

-

-

-3,550

-4,076

-4,982

-

-3,428

38,719

-9,359

-

-6,882

-7,834

-11,980

-33,196

-11,375

-17,126

-19,186

-11,611

-16,974

-12,605

-13,682

-12,534

-9,070

-8,575

-8,800

-15,769

-9,490

-20,593

-9,455

-19,140

-7,497

-10,776

-10,359

-7,140

-5,427

Basic and diluted loss per share
Preferred dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

67

88

107

131

150

170

186

-

53

Loss from continuing operations

-

-

-

-

-

-

-

-

-

-4,021

-3,428

-1,967

-6,571

-

-6,031

-7,669

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,297

-8,488

-7,151

-7,877

-8,888

-6,535

-10,071

-8,770

-

-

Income from discontinued operations - net of taxes

-

-

-

-

-

-

-

-

-

1,069

0

40,686

-2,788

-

-851

-165

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,207

77

-13,354

-1,470

-

-811

-533

-

-

-

Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders

-3,990

-

-

-

-4,367

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders

-

-

-4,898

-5,140

-

-

-3,550

-4,076

-4,982

-

-3,428

38,719

-9,359

-

-6,882

-7,834

-

-

-

-

-

-

-

-

-

-

-9,070

-8,575

-8,800

-15,769

-9,490

-20,593

-9,455

-19,140

-7,497

-10,776

-10,359

-7,140

-5,427

Basic and diluted loss per share:
Continuing operations (in usd per share)

-

-

-

-

-

-

-

-

-

-

-0.38

-0.22

-0.78

-

-0.95

-1.30

-

-

-

-

-

-

-

-

-

-

-

-

-

-1.42

-0.57

-0.53

-0.07

-0.07

-0.07

-0.13

-0.12

-

-

Discontinued operations (in usd per share)

-

-

-

-

-

-

-

-

-

-

0.00

4.56

-0.33

-

-0.13

-0.03

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.31

0.01

-0.99

-0.01

-0.12

-0.01

-0.01

-0.01

-

-

Caladrius Biosciences, Inc. common stockholders (in usd per share)

-0.38

-0.48

-0.47

-0.49

-0.44

-0.37

-0.36

-0.42

-0.52

-

-0.38

4.34

-1.12

-

-1.09

-1.33

-2.09

-10.26

-2.06

-3.84

-0.51

-0.31

-0.48

-0.40

-0.49

-0.46

-0.45

-0.46

-0.53

-1.75

-0.64

-1.53

-0.08

-0.19

-0.08

-0.13

-0.14

-0.13

-0.11

Weighted average common shares outstanding
Weighted average common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,698

-84,699

14,819

13,441

111,806

106,071

94,102

80,567

73,654

56,777

48,771

Basic and diluted shares

10,623

10,469

10,411

10,393

10,027

9,862

9,745

9,592

9,557

-

9,093

8,926

8,386

-

6,323

5,907

5,738

-

5,523

4,457

37,594

-

35,053

31,739

28,120

-

20,203

18,503

-

-

-

-

-

-

-

-

-

-

-

Available for sale securities - net unrealized (loss) gain

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

1

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

1

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,393

-17,156

-19,232

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to noncontrolling interests

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16

-31

-44

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,376

-17,124

-19,188

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

94,089

80,581

73,654

56,777

48,771